PrecisemAb Biotech Co,.Ltd
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Our Universal Antibody Lock™ technology is an innovative, proprietary platform designed to generate conditionally-activated antibody therapeutics for a variety of antibody formats, including monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. This technology not only enhances antibody selectivity but also reduces on-target toxicity, delivering safer and more effective therapeutic solutions for patients.
The content above was translated by Ai
Founded Year
2020
Unified Business No.
83392679
Status
Closed
Number of Employees
0
Total capital
1,000,000 (NT$)
Location of Company
Taiwan
, Kaohsiung City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Now renamed as Shuo Zhun Biotechnology Co., Ltd., PrecisemAb was jointly established by a team led by Chair Professor Tian-Lu Cheng, Dr. Yun-Chi Lu, and Dr. Yi-An Cheng of Kaohsiung Medical University. Having deeply cultivated the field of antibody engineering for 25 years, Professor Tian-Lu Cheng successfully developed the globally unique "Antibody Lock" technology, which can effectively enhance the selectivity of antibody drugs toward disease areas and reduce drug side effects, bringing a revolutionary breakthrough to the safety of antibody drugs. Upholding the spirit of "contributing to society with professionalism," Professor Tian-Lu Cheng will lead the team to continuously create a more reassuring treatment environment for patients.
The content above was translated by Ai
